Eli Lilly announced an agreement to acquireVersanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases for $1.925B in cash.
Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to block activin and myostatin signaling. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study alone and in combination with semaglutide in adults who are overweight or obese.
Combining incretins with bimagrumab has the potential to further reduce fat mass while preserving muscle mass and may lead to better outcomes for people living with obesity and obesity-related complications.
What You Should Know: – BehaVR and Fern Health have merged to create RealizedCare, a new company that will provide digital care management solutions for
Share this article The companies will leverage Nona’s Harbour Mice technology platform to discover antibodies. Credit: Matej Kastelic / Shutterstock.com. Nona Biosciences has entered a
Eli Lilly Acquires Obesity Drug Maker Versanis for $1.9B – M&A
by Fred Pennic Leave a Comment
What You Should Know:
BehaVR and Fern Health Merge to Form RealizedCare Focused on Digital Therapeutics
What You Should Know: – BehaVR and Fern Health have merged to create RealizedCare, a new company that will provide digital care management solutions for
Nona Biosciences and Evive enter antibody discovery deal
Share this article The companies will leverage Nona’s Harbour Mice technology platform to discover antibodies. Credit: Matej Kastelic / Shutterstock.com. Nona Biosciences has entered a
GSK CEO Emma Walmsley on the new Trump administration, trust, AI and China
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS